US venture capital firm founded by Christine Aylward in 2018, backing companies at the intersection of deep technology and life sciences. Magnetic Ventures invests in AI, machine learning, multiomics, drug discovery, precision medicine and technology-enabled healthcare, typically entering at seed or Series A with initial checks of $1–6 million. Its current offices are in Boston, Miami and Research Triangle Park. The team comprises a founder and managing partner, two venture partners and three advisers. Portfolio companies include Proxima Bio, Weave Bio, Relation Therapeutics, Deep Genomics, Transition Bio and Gilgamesh Pharmaceuticals. Magnetic Ventures Management, LLC reports Funds I and II; reported asset values and fundraising targets are distinct from completed fund closings. This US healthcare firm is separate from Berlin infrastructure investor Magnetic Capital.